In contrast, the combination treatment induced minimal cytotoxic effects in normal human ovarian surface epithelial cells (HOSEs), indicating DTCD did not abrogate the potential tumor selectivity of TRAIL. The gene discussed is TNFSF10; the disease is neoplasm.